Paper33535978
Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
Zhang R and 8 others. BMC Cancer, 2021. Cited by 21 papers, by iCite.
Cite this record
ConductScience Library. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma. Papers, record 33535978. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33535978
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bile Duct Neoplasms | Major topic |
| Biomarkers, Tumor | Major topic |
| Cholangiocarcinoma | Major topic |
| Gene Expression Regulation, Neoplastic | Major topic |
| Mutation | Major topic |
| Nomograms | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Female | |
| Follow-Up Studies | |
| Gene Expression Profiling | |
| Humans | |
| Male | |
| Middle Aged | |
| Prognosis | |
| Survival Rate | |
| Exome Sequencing |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 62076194 | National Natural Science Foundation of China | PubMed | ||
| 2017ZDXM-SF-055 | Key Research and Development Plan of Shaanxi Province | PubMed | ||
| No. 2017KW-060 | Key Research and Development Plan of Shaanxi Province | PubMed | ||
| No. 2020SF-070 | the General Project of Natural Science Basic Research Plan of Shaanxi Province | PubMed | ||
| XJTU1AF-CRF-2018-022 | Clinical Research Fund of the First Affiliated Hospital of Xi'an Jiaotong University | PubMed |
Source PubMed
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26258846 | Genomic spectra of biliary tract cancer. | Nat Genet | 2015 | https://conductscience.org/library/papers/26258846 | PubMed |
| 2 | 25526346 | Mutational landscape of intrahepatic cholangiocarcinoma. | Nat Commun | 2014 | https://conductscience.org/library/papers/25526346 | PubMed |
| 3 | 31995247 | Prognostic role of tumor mutation burden in hepatocellular carcinoma after radical hepatectomy. | J Surg Oncol | 2020 | https://conductscience.org/library/papers/31995247 | PubMed |
| 4 | 28667006 | Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma. | Cancer Discov | 2017 | https://conductscience.org/library/papers/28667006 | PubMed |
| 5 | 29337637 | Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine? | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29337637 | PubMed |
| 6 | 32293336 | Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma. | BMC Cancer | 2020 | https://conductscience.org/library/papers/32293336 | PubMed |
| 7 | 24718873 | Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis. | JAMA Surg | 2014 | https://conductscience.org/library/papers/24718873 | PubMed |
| 8 | 29278425 | Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. | Hepatology | 2018 | https://conductscience.org/library/papers/29278425 | PubMed |
| 9 | 18234754 | Oncogenes and cancer. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18234754 | PubMed |
| 10 | 26059651 | Management and Outcomes of Patients with Recurrent Intrahepatic Cholangiocarcinoma Following Previous Curative-Intent Surgical Resection. | Ann Surg Oncol | 2016 | https://conductscience.org/library/papers/26059651 | PubMed |
| 11 | 29193010 | Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. | Br J Surg | 2018 | https://conductscience.org/library/papers/29193010 | PubMed |
| 12 | 31700863 | Genome-wide mutation profiling and related risk signature for prognosis of papillary renal cell carcinoma. | Ann Transl Med | 2019 | https://conductscience.org/library/papers/31700863 | PubMed |
| 13 | 29654927 | Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief Report. | J Thorac Oncol | 2018 | https://conductscience.org/library/papers/29654927 | PubMed |
| 14 | 26409434 | Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management. | Cancer Lett | 2016 | https://conductscience.org/library/papers/26409434 | PubMed |
| 15 | 31337644 | Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/31337644 | PubMed |
| 16 | 30816954 | Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. | JAMA Oncol | 2019 | https://conductscience.org/library/papers/30816954 | PubMed |
| 17 | 31038663 | Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. | Ann Oncol | 2019 | https://conductscience.org/library/papers/31038663 | PubMed |
| 18 | 30526857 | Systematic identification of mutations and copy number alterations associated with cancer patient prognosis. | Elife | 2018 | https://conductscience.org/library/papers/30526857 | PubMed |
| 19 | 32606456 | Cholangiocarcinoma 2020: the next horizon in mechanisms and management. | Nat Rev Gastroenterol Hepatol | 2020 | https://conductscience.org/library/papers/32606456 | PubMed |
| 20 | 32256810 | Comprehensive genomic profile of cholangiocarcinomas in China. | Oncol Lett | 2020 | https://conductscience.org/library/papers/32256810 | PubMed |
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42602860 | Ultra-low-pass whole-genome sequencing of bile cfDNA in patients with biliary strictures. | eGastroenterology | 2026 | https://conductscience.org/library/papers/42602860 | PubMed |
| 41514603 | A Phase II Study of Toripalimab in Combination with Gemcitabine and 5-Fluorouracil as First-Line Therapy for Advanced or Metastatic Biliary Tract Carcinoma. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41514603 | PubMed |
| 40831993 | NAT2: A Novel Target in Intrahepatic Cholangiocarcinoma and its Role in Modulating Tumor Behavior. | Clin Med Insights Oncol | 2025 | https://conductscience.org/library/papers/40831993 | PubMed |
| 39633593 | TMB is associated with the prognosis of egfr-mutated non-small cell lung cancer in Xuanwei, China. | Biomark Med | 2024 | https://conductscience.org/library/papers/39633593 | PubMed |
| 38461467 | Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma. | J Gastroenterol | 2024 | https://conductscience.org/library/papers/38461467 | PubMed |
| 38161496 | Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma (2022 version). | J Clin Transl Hepatol | 2023 | https://conductscience.org/library/papers/38161496 | PubMed |
| 37895447 | Targeted Therapies in Advanced Cholangiocarcinoma. | Life (Basel) | 2023 | https://conductscience.org/library/papers/37895447 | PubMed |
| 37626908 | Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis. | Cells | 2023 | https://conductscience.org/library/papers/37626908 | PubMed |
| 37434687 | Identification and evaluation of a risk model predicting the prognosis of breast cancer based on characteristic signatures. | Transl Cancer Res | 2023 | https://conductscience.org/library/papers/37434687 | PubMed |
| 36452508 | High tumor mutation burden indicates better prognosis in colorectal cancer patients with KRAS mutations. | Front Oncol | 2022 | https://conductscience.org/library/papers/36452508 | PubMed |
| 36290849 | Precision Oncology in Canada: Converting Vision to Reality with Lessons from International Programs. | Curr Oncol | 2022 | https://conductscience.org/library/papers/36290849 | PubMed |
| 35127895 | High tumor mutation burden indicates a poor prognosis in patients with intrahepatic cholangiocarcinoma. | World J Clin Cases | 2022 | https://conductscience.org/library/papers/35127895 | PubMed |
| 34947843 | Development and Validation of a Mutational Burden-Associated LncRNA Signature for Improving the Clinical Outcome of Hepatocellular Carcinoma. | Life (Basel) | 2021 | https://conductscience.org/library/papers/34947843 | PubMed |
| 34282753 | Current Advances in Basic and Translational Research of Cholangiocarcinoma. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34282753 | PubMed |
| 34249744 | ARID1A Variations in Cholangiocarcinoma: Clinical Significances and Molecular Mechanisms. | Front Oncol | 2021 | https://conductscience.org/library/papers/34249744 | PubMed |
Genes29
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33535978
GET https://conductscience.org/api/papers/v1/33535978/references?page=2